Charlson comorbidity index (CCI) in diffuse large B-cell lymphoma: a new pproach in a multicenter study

Basit Öğe Kaydı
dc.authoridRafet Eren / 0000-0003-0973-6279
dc.authorscopusidRafet Eren / 57148626000en_US
dc.authorwosidRafet Eren / GCU-9466-2022en_US
dc.contributor.authorEren, Rafet
dc.contributor.authorSerin, İstemi
dc.contributor.authorAtak, Süheyla
dc.contributor.authorPirdal, Betül Zehra
dc.contributor.authorNizam, Nihan
dc.contributor.authorGemici, Aliihsan
dc.contributor.authorAydın, Demet
dc.contributor.authorDemirel, Naciye
dc.contributor.authorDoğan, Esma Evrim
dc.contributor.authorYokuş, Osman
dc.date.accessioned2022-11-07T07:27:50Z
dc.date.available2022-11-07T07:27:50Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Hastaneen_US
dc.description.abstractPurpose: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of adult lymphomas. The incidence of DLBCL increases with age and has a fairly rapid fatal course without treatment. Patients often have difficulty tolerating standard chemotherapy regimens due to their comorbidities. Charlson Comorbidity Index (CCI), which is calculated by considering 19 different comorbidities, was developed in 1987 and is widely used for mortality prediction in cancer patients. Literature data on CCI and hematological malignancies are limited. Main aim in this study is to evaluate the effectiveness of CCI and compare to the International Prognostic Index (IPI) scoring system in the DLBCL patient group. Methods: A total of 170 patients diagnosed with DLBCL between 1.1.2002- 1.12.2020 were included in the study. Statistical analyzes were performed among patients whose IPI and CCI scores were recorded by considering baseline data. Results: The median age of patients was 58 (range: 17–84). Thirty-five (20.6%) patients had stage III and 76 (44.7%) had stage IV disease. When the CCI, IPI and ECOG scores were compared with the mortality status of the patients as a reference, AUCs were resulted as 0.628 (95% CI: 0.506–0.749), 0.563 (95% CI: 0.484–0.639) and 0.672 (95% CI: 0.596–0.743), respectively. There was no significant difference between the ROC curves of CCI, IPI and ECOG scores. Patients with a CCI score of ? 4 had shorter OS comperad to those with a score of < 4. Conclusion: Rather than claiming that CCI is superior to IPI, ECOG or another scoring system in a single-center patient population, it should be stated that CCI is also an effective scoring system in patients diagnosed with DLBCL.en_US
dc.identifier.citationEren, R., Serin, I., Atak, S., Pirdal, B. Z., Nizam, N., Gemici, A., . . . Yokus, O. (2022). Charlson comorbidity index (CCI) in diffuse large B-cell lymphoma: A new approach in a multicenter study. Indian Journal of Hematology and Blood Transfusion, doi:10.1007/s12288-022-01567-5en_US
dc.identifier.doi10.1007/s12288-022-01567-5en_US
dc.identifier.scopus2-s2.0-85139131507en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.urihttps://doi.org/10.1007/s12288-022-01567-5
dc.identifier.urihttps://hdl.handle.net/20.500.12713/3244
dc.identifier.wosWOS:000862902900002en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorEren, Rafet
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofIndian Journal of Hematology and Blood Transfusionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCharlson Comorbidity Indexen_US
dc.subjectDiffuse Large B-cell Lymphomaen_US
dc.subjectEfficacyen_US
dc.subjectPrognosisen_US
dc.titleCharlson comorbidity index (CCI) in diffuse large B-cell lymphoma: a new pproach in a multicenter studyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
s12288-022-01567-5.pdf
Boyut:
913.3 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
İSÜ Hastaneleri Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu